Active — Not RecruitingNot Applicable

CONFIRM EXTENSION - Long-term Follow-up Study of Patients Treated with AGN1 LOEP

Belgium60 participantsStarted 2020-08-28

Plain-language summary

The study is designed as a multi-center study within Europe in up to 60 patients treated with the AGN1 LOEP Kit in CONFIRM. This will be a non-randomized and non-blinded study. The study will collect long-term follow-up data on the safety and clinical performance of AGN1 LOEP. To qualify, subjects must have previously consented, enrolled, and been treated with the AGN1 LOEP kit in CONFIRM (AgNovos Study PST-EU-101.1). Follow-up evaluations will be conducted at 24, 36, 48 and 60 months from the date the subject originally received the AGN1 LOEP treatment. Subjects will receive DXA and X-ray imaging at the 24- and 60-month follow-up visits. The 36- and 48-month follow-up evaluations will be conducted by phone. All timepoints will include general health and medical record review.

Who can participate

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Subject had previously enrolled in CONFIRM and received AGN1 LOEP treatment. * Subject has willingness, ability, and commitment to participate in baseline and follow-up evaluations for the full length of the study. * Subject is capable of giving written informed consent to participate in the study. Exclusion Criteria: * Subject was withdrawn from CONFIRM. * Subject has severe comorbidity or poor general physical/mental health that, in the opinion of the Investigator, will not allow the subject to be a good study candidate.

What they're measuring

Change in DXA score at 24 months

Timeframe: 24 months

Trial details

NCT IDNCT04511364

SponsorAgNovos Healthcare, LLC

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-12

View on ClinicalTrials.gov More Osteoporosis trials